Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jul 17:10:72.
doi: 10.1186/1742-4690-10-72.

Development of prophylactic vaccines against HIV-1

Torben Schiffner  1 , Quentin J Sattentau, Lucy Dorrell
Affiliations
Review

Development of prophylactic vaccines against HIV-1

Torben Schiffner et al. Retrovirology. .

Abstract

The focus of most current HIV-1 vaccine development is on antibody-based approaches. This is because certain antibody responses correlated with protection from HIV-1 acquisition in the RV144 phase III trial, and because a series of potent and broad spectrum neutralizing antibodies have been isolated from infected individuals. Taken together, these two findings suggest ways forward to develop a neutralizing antibody-based vaccine. However, understanding of the correlates of protection from disease in HIV-1 and other infections strongly suggests that we should not ignore CTL-based research. Here we review recent progress in the field and highlight the challenges implicit in HIV-1 vaccine design and some potential solutions.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Model of HIV-1 envelope glycoprotein gross structure and broadly neutralizing antibody binding surfaces. The functional HIV-1 envelope glycoproteins are made up of two subunits, the outer (surface) receptor binding subunit gp120, and the membrane-spanning, fusion-mediating subunit, gp41. The viral envelope is represented in beige, and the intraviral portion of gp41 is not represented. These subunits are non-covalently linked into a trimer of heterodimers. Glycans are not shown, but there are on average 25 N-linked glycan sites that represent 50% of the total mass of gp120. Broadly neutralizing monoclonal antibody epitope clusters are represented as follows: the gp120 CD4 binding surface (green); an epitope cluster of at the tip of the trimer that depends upon conservation of Env quaternary folding (mauve); the gp120 epitope cluster of glycopeptide-reactive antibodies (pink); the gp41 membrane proximal external region (MPER) cluster (blue). The antibodies listed are non-exhaustive examples of a growing collection. Broadly neutralizing antibodies isolated pre-2009 are lettered in grey, post-2009 in black.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McMichael AJ, Haynes BF. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol. 2012;13(5):423–427. doi: 10.1038/ni.2264. - DOI - PMC - PubMed
    1. Walker BD, Ahmed R, Plotkin S. Moving ahead an HIV vaccine: use both arms to beat HIV. Nat Med. 2011;17(10):1194–1195. doi: 10.1038/nm.2529. - DOI - PubMed
    1. Nabel GJ. Designing tomorrow’s vaccines. N Engl J Med. 2013;368(6):551–560. doi: 10.1056/NEJMra1204186. - DOI - PMC - PubMed
    1. Johnston MI, Fauci AS. HIV vaccine development–improving on natural immunity. N Engl J Med. 2011;365(10):873–875. doi: 10.1056/NEJMp1107621. - DOI - PubMed
    1. Mouquet H, Nussenzweig MC. HIV: Roadmaps to a vaccine. Nature. 2013;496(7446):441–442. doi: 10.1038/nature12091. - DOI - PubMed

Publication types

MeSH terms